Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 26, 2009

Neuraltus Closes $17M Series A Financing

  • Neuraltus Pharmaceuticals completed a $17 million series A financing round with Latterell Venture Partners, VantagePoint Venture Partners, and Adam Street Partners. Each venture firm will have a seat on Neuraltus' board of directors.

    The funding is expected to cover the costs of Phase I and II testing for Neuraltus' ALS therapy, a treatment to reduce dyskinesia in Parkinson's patients, and a drug therapy for Gaucher's disease.

    "Neuraltus offers a strong pipeline of compounds for the treatment of serious neurological diseases for which there are few if any clinical options," says James Woody, Ph. D. of Latterell Venture Partners.


Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.